Clarity in every comparison.What changed. Why it matters.
Canadian medication approvals, recalls, price developments and practical reading. In-depth explanations, practical context and links to the original evidence.
19 articles · News and explainers
GLP-1 sales in Canada are on pace for a new record in 2026
About $2.4 billion in first-half retail sales puts Canada on a record-setting trajectory, according to IQVIA figures reported by The Globe and Mail.
Why a provider’s starting fee needs context
A free first visit can reduce an initial expense, but it does not describe the cost of continuing care.
Zepbound without insurance: questions behind the published range
Without insurance, the most useful Zepbound cost is the complete cash amount for your exact fill.
Apo-Semaglutide: a lot-specific dose-display recall
A recall headline should lead to a package check, not a conclusion about every medicine with the same ingredient.
Dr. Reddy’s semaglutide: August impurity recall
An impurity recall requires attention to the affected product records and lots.
Mounjaro’s Canadian indication extends to ages 10–17 with type 2 diabetes
The age range in a drug-approval headline is only part of the authorization.
Ozempic savings card expands to eligible privately insured patients
A savings-card announcement describes program access, not a guaranteed payment for every prescription.
Sevmia approval: the reference product matters
The Sevmia announcement is important because its reference product differs from earlier Canadian generic semaglutide approvals.
Zepbound receives a Canadian sleep-apnea indication
A new indication can change the information a clinician considers without settling an individual treatment decision.
Talking about semaglutide: decide what you want to share
You can decide how much of a treatment conversation to share with family or friends.
Generic semaglutide in Canada: approvals, prices and practical questions
Generic semaglutide in Canada is a product-specific story: which medicine was authorized, what the pharmacy supplies, and what the final quote includes.
Novo Nordisk and Rexall announce a home-delivery partnership
Home delivery can change how a prescription reaches you without changing which costs remain payable.
A second generic semaglutide approval adds an Apotex option
The second Canadian generic semaglutide approval added another manufacturer to follow.
Canada’s first generic semaglutide approval: what changed
Canada’s first generic semaglutide approval was a regulatory milestone, not a universal pharmacy launch.
Mounjaro prices: make the package and supply period visible
A useful Mounjaro comparison starts with the presentation, quantity and supply period—not the largest price printed on a page.
Ozempic price ranges in Canada: how to read the headline
An Ozempic price range is only useful when the package and discount assumptions travel with it.
Ozempic’s Canadian cardiovascular indication expands
News about an additional cardiovascular indication needs to be read with the population and product intact.
Health Canada warns about fake and unauthorized GLP-1 products
A familiar ingredient name, convincing packaging or a low advertised price does not establish that an online product is authorized in Canada.
Rybelsus receives a Canadian cardiovascular indication
Rybelsus is an oral semaglutide product, so its approval news should remain distinct from news about injectable semaglutide.